Literature DB >> 16305429

Erythromycin ethosomal systems: physicochemical characterization and enhanced antibacterial activity.

Biana Godin1, Elka Touitou.   

Abstract

The rationale behind this work was that a permeation enhancing carrier could facilitate the transport of antibacterial molecules through the two biological barriers: stratum corneum of the skin and bacterial membrane/cell wall. To this end, erythromycin ethosomes (EE) were designed and characterized, and their antibacterial efficiency was evaluated in vitro and in vivo. TEM, CLSM, DLS, DSC and ultracentrifugation tests indicate that EE are small unilamellar soft vesicles encapsulating 78.6% erythromycin. The compositions were stable for at least one year at room temperature. In live/dead viability/cytotoxicity tests, EE systems were nontoxic to cultured 3T3 dermal fibroblasts. Susceptibility studies conducted on three bacterial strains (B. subtilis ATCC 6633, S. aureus ATCC 29213 and S. aureus clinically resistant to erythromycin) showed significantly larger inhibition zones for EE as compared to erythromycin in hydroethanolic solutions. Moreover, EE reduced erythromycin MIC as compared to control solution: from 2.5 to 1.25 microg/ml for S. aureus ATCC 29213 and from 12.5 to 5.0 microg/ml for clinically isolated resistant S. aureus strain. Ethosomal erythromycin applied to the skin of ICR mice inoculated with 10(7)cfu S. aurues ATCC 29213 resulted in complete inhibition of infection. On the contrary, when hydroethanolic solution of erythromycin was applied, deep dermal and subcutaneous abscesses developed within five days after challenge. On day seven, a similar number of S. aureus colonies (1.06x10(7) vs. 0.90x10(7) cfu/g tissue) were isolated from the untreated wounds or treated with hydroethanolic erythromycin. For these animals, histopathological examination showed necrosis, destroyed skin structures and dense infiltrates of neutrophils and macrophages. These findings show that ethosomes are efficient carriers for erythromycin delivery to bacteria localized within the deep skin strata for eradication of staphylococcal infections.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16305429     DOI: 10.2174/1567201054367931

Source DB:  PubMed          Journal:  Curr Drug Deliv        ISSN: 1567-2018            Impact factor:   2.565


  12 in total

1.  Development of nanovesicular systems for dermal imiquimod delivery: physicochemical characterization and in vitro/in vivo evaluation.

Authors:  Man Ma; Jinping Wang; Fang Guo; Mingzhu Lei; Fengping Tan; Nan Li
Journal:  J Mater Sci Mater Med       Date:  2015-05-20       Impact factor: 3.896

Review 2.  Delivering macrolide antibiotics to heal a broken heart - And other inflammatory conditions.

Authors:  Vincent J Venditto; David J Feola
Journal:  Adv Drug Deliv Rev       Date:  2022-03-30       Impact factor: 17.873

3.  Enhanced transdermal delivery of salbutamol sulfate via ethosomes.

Authors:  Ehab R Bendas; Mina I Tadros
Journal:  AAPS PharmSciTech       Date:  2007-12-14       Impact factor: 3.246

Review 4.  Ethosomes as Nanocarriers for the Development of Skin Delivery Formulations.

Authors:  Ana Cláudia Paiva-Santos; Ana Luísa Silva; Catarina Guerra; Diana Peixoto; Miguel Pereira-Silva; Mahdi Zeinali; Filipa Mascarenhas-Melo; Ricardo Castro; Francisco Veiga
Journal:  Pharm Res       Date:  2021-05-25       Impact factor: 4.200

5.  Preparation of a ligustrazine ethosome patch and its evaluation in vitro and in vivo.

Authors:  Xingyan Liu; Hong Liu; Jianqiang Liu; Zhiwei He; Congcong Ding; Guoliang Huang; Weihua Zhou; Leshan Zhou
Journal:  Int J Nanomedicine       Date:  2011-01-27

6.  Therapeutic and cosmeceutical potential of ethosomes: An overview.

Authors:  Poonam Verma; K Pathak
Journal:  J Adv Pharm Technol Res       Date:  2010-07

Review 7.  Ethosomal nanocarriers: the impact of constituents and formulation techniques on ethosomal properties, in vivo studies, and clinical trials.

Authors:  Ibrahim M Abdulbaqi; Yusrida Darwis; Nurzalina Abdul Karim Khan; Reem Abou Assi; Arshad A Khan
Journal:  Int J Nanomedicine       Date:  2016-05-25

Review 8.  Liposomes with an Ethanol Fraction as an Application for Drug Delivery.

Authors:  Ewa Pilch; Witold Musiał
Journal:  Int J Mol Sci       Date:  2018-11-29       Impact factor: 5.923

Review 9.  Phospholipid Vesicles for Dermal/Transdermal and Nasal Administration of Active Molecules: The Effect of Surfactants and Alcohols on the Fluidity of Their Lipid Bilayers and Penetration Enhancement Properties.

Authors:  Hiba Natsheh; Elka Touitou
Journal:  Molecules       Date:  2020-06-27       Impact factor: 4.411

Review 10.  Topical Administration of Drugs Incorporated in Carriers Containing Phospholipid Soft Vesicles for the Treatment of Skin Medical Conditions.

Authors:  Elka Touitou; Hiba Natsheh
Journal:  Pharmaceutics       Date:  2021-12-10       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.